Condition: Severe Malaria · Severe Anaemia · Sponsor: Institut de Recherche Clinique du Benin
The proposed research aims to conduct implementation trials in Benin, co-designed with national stakeholders, to evaluate different delivery strategies for optimizing health system delivery of post-discharge malaria chemoprevention (PDMC) drugs and adherence to PDMC. This chemoprevention strategy is effective in reducing hospital readmissions and deaths after discharge. However, there is no clear delivery platform for PDMC, and adherence to the 3-day dosing regimen, provided monthly three times after discharge, is a potential limitation. The current trial will provide evidence-based data on acceptability, feasibility, and cost-effectiveness to aid decision-makers. The evidence generated will be used to support the effective implementation and scale-up of PDMC in high malaria-endemic areas such as Benin.
This description comes directly from the study's public registry record.
Manfred Accrombessi, MD, PhD · 22966033138 · accrombessimanfred@gmail.com
Achille Massougbodji, MD · 22996807027 · massougbodjiachille@yahoo.fr
Always discuss trial participation with your own doctor first.
| Goho Departmental Hospital Centre | Abomey, Benin | Not Yet Recruiting |
| Centre Hospitalier Universitaire de la Mere et de l'Enfant Lagune (CHU-MEL) | Cotonou, Benin | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06601712